Flagship Pioneering
Flagship Pioneering is an American life sciences venture capital and bioplatform innovation company based in Cambridge, Massachusetts. It conceives, creates, resources, and grows first-in-category ventures in biotechnology, healthcare, and sustainability, having founded over 100 companies including Moderna.
57% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 4 prior). Average disclosed round size is $115.2M (across 49 rounds with reported amounts).
Portfolio
42
Fund Size
$3.6B
Top Stage
Unknown
Last 12 Mo
2
Team
Yvonne Hao
Chief Operating Officer and General Partner
Jeffrey Luber
Growth Partner
Yasir Al-Wakeel
CEO-Partner and Chief Executive Officer of Vesalius Therapeutics
Anthony Picariello
Senior Director, Fund Finance and Compliance
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Harbinger Health | Unknown | $100M | Apr 2026 |
 Mirai Bio | Unknown | $50M | Jan 2026 |
 Lila Sciences | Seed | $200M | Mar 2025 |
 Inari Agriculture, Inc. | Growth | $144M | Jan 2025 |
| IInari Agriculture | Unknown | $144M | Jan 2025 |
 Ampersand Biomedicines | Series B | $65M | Jan 2025 |
 Etiome | Series A | $50M | Jan 2025 |
 Abiologics | Unknown | $50M | Jul 2024 |
 Seres Therapeutics | Series E | $113M | Jan 2024 |
| Harbinger Health | Unknown | $140M | Sep 2023 |
 Indigo Agriculture | Growth | $250M | Sep 2023 |
 Generate Biomedicines | Series C | $273M | Sep 2023 |
 Alltrna | Series B | $109M | Aug 2023 |
| Ampersand Biomedicines | Series B | $65M | Jan 2023 |
 Quotient Therapeutics | Unknown | $50M | Jan 2023 |
| Harbinger Health | Series B | — | Jan 2023 |
| SSenda Biosciences | Series C | $123M | Aug 2022 |
 Apriori Bio | Unknown | $50M | Jul 2022 |
 Vesalius Therapeutics | Unknown | $75M | Mar 2022 |
| LLaronde Bio | Series B | $440M | Aug 2021 |
 Ring Therapeutics | Series B | $117M | Jul 2021 |
 Ring | Series B | $117M | Jul 2021 |
| SSenda Biosciences | Series B | $55M | Jun 2021 |
 Invaio Sciences | Series C | $88.9M | May 2021 |
 Repertoire Immune Medicines | Series B | $189M | Apr 2021 |
Top Co-Investors
Last updated: 8 September 2026